Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 10, 2000Neurology

Rituximab for myasthenia gravis developing after bone marrow transplant

View Full Paper
Ask AI
Bookmark
Share

Authors

FZFrancesco ZajaUniversity of SienaDRDomenico RussoBrescia UniversityGFG C FugaUniversity of Udine

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zaja et al. (2000) studied this question.

synapsesocial.com/papers/6a720dda5671bbf00bc301dehttps://doi.org/10.1212/wnl.55.7.1062-a
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD201994 · 1,948 citations
  2. 2IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab1999 · 251 citations
  3. 3The B cell surface molecule B1 is functionally linked with B cell activation and differentiation.1985 · 230 citations
  4. 4Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow1987 · 49 citations
  5. 5Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes1986 · 146 citations